Many new pharmaceuticals are based on large biomolecules like proteins. Even small differences in the protein structure can cause significant changes in the efficacy and safety of these drugs. Furthermore, these large molecules are difficult to characterize without advanced instrumentation and methods. Current technologies still struggle with robustness and reproducibility. This study aims to introduce new technology to improve the reliability of protein pharmaceutical characterization.
Diagnostic tests that currently direct patient therapy in cancer and other diseases are more typically performed at the genetic level, despite the fact that the beneficial response to drugs and the development of resistance are rooted in the proteins that comprise the cell’s signaling pathways. We argue that this is a major gap, as proteomics can be used to understand how cells respond to inhibitors, thereby identifying patients who are responding positively at the molecular level, as well as patients who are developing resistance through the reorganization of the cell’s signaling network.
Join a thriving innovation ecosystem. Subscribe now